Hemera Biosciences

Medford, United States Founded: 2010 • Age: 16 yrs
Anti-complement gene therapies for AMD treatment are developed pre-clinically.
Annual revenue - Latest available
Total funding $3.8M 1 rounds
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Hemera Biosciences

Hemera Biosciences is a company based in Medford (United States) founded in 2010. Hemera Biosciences has raised $3.75 million across 1 funding round. Hemera Biosciences operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

  • Headquarter Medford, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $3.75 M (USD)

    in 1 rounds

  • Latest Funding Round
    $3.75 M (USD), Series A

    Apr 01, 2013

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Hemera Biosciences

Hemera Biosciences has successfully raised a total of $3.75M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.75 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by Hemera Biosciences

Investments
Premium access

Investment portfolio details for Hemera Biosciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Hemera Biosciences

Premium access

Detailed financials for Hemera Biosciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Hemera Biosciences Comparisons

Hemera Biosciences Primary company
Description
Anti-complement gene therapies for AMD treatment are develop...
Location
Medford, United States
Founded Year
2010
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Hemera Biosciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Hemera Biosciences

Hemera Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Locked Locked Locked
Gene therapies for rare diseases are developed to treat patients.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
Provider of cell therapies to treat cancer and hematologic conditions
Premium access

Detailed competitors of Hemera Biosciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Hemera Biosciences

Premium access

Complete news archive for Hemera Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hemera Biosciences

Hemera Biosciences was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Hemera Biosciences is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.

Hemera Biosciences is a funded company, having raised a total of $3.75M across 1 funding round to date.

Hemera Biosciences was founded in 2010 and is based in Medford, United States. Focus is placed on the biotechnology sector, where anti-complement gene-based therapies are developed for dry and wet age-related macular degeneration (AMD). This condition represents the primary cause of blindness in older adults, with no options available for 90 of dry AMD cases. Preclinical models have shown reductions in complement-mediated damage to eye tissues through proprietary recombinant molecules.

Hemera Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available